Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Benjamin Y. Kong"'
Autor:
Lauren Julia Brown, Victor Khou, Chris Brown, Marliese Alexander, Dasantha Jayamanne, Joe Wei, Lauren Gray, Wei Yen Chan, Samuel Smith, Susan Harden, Antony Mersiades, Lydia Warburton, Malinda Itchins, Jenny H. Lee, Nick Pavlakis, Stephen J. Clarke, Michael Boyer, Adnan Nagrial, Eric Hau, Ines Pires da Silva, Steven Kao, Benjamin Y. Kong
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionBrain metastases commonly occur in patients with non-small cell lung cancer (NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1 mutation, is either chemoimmunotherapy or anti-PD-1 monotherapy. Traditionally, pat
Externí odkaz:
https://doaj.org/article/091bc647cc054317a5b3754310f54a38
Autor:
Georgia K. B. Halkett, Lauren J. Breen, Melissa Berg, Rebecca Sampson, Hao-Wen Sim, Hui K. Gan, Benjamin Y. Kong, Anna K. Nowak, Bryan W. Day, Rosemary Harrup, Melissa James, Frank Saran, Brett Mcfarlane, Chris Tse, Eng-Siew Koh
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9928-9955 (2022)
The aim of this project was to determine research priorities, barriers, and enablers for adult primary brain tumour research in Australia and New Zealand. Consumers, health professionals, and researchers were invited to participate in a two-phase mod
Externí odkaz:
https://doaj.org/article/6cd87a96459d43ed8dda66d8c3a38599
Autor:
Joe Q. Wei, Alexander Yuile, Malinda Itchins, Benjamin Y. Kong, Bob T. Li, Nick Pavlakis, David L. Chan, Stephen J. Clarke
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1827 (2023)
Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in ef
Externí odkaz:
https://doaj.org/article/25aa28393ada4a768db8ac249106808b
Autor:
Benjamin Y. Kong, Holly Bolton, Julius W. Kim, Pablo A. Silveira, Phillip D. Fromm, Georgina J. Clark
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Monoclonal antibodies targeting co-inhibitory immune checkpoint molecules have been successful in clinical trials of both solid and hematological malignancies as acknowledged by the 2018 Nobel Prize in Medicine, however improving clinical response ra
Externí odkaz:
https://doaj.org/article/b82281137cf74eb49b8db3637775a506
Autor:
Shelley J. E. Hwang, Benjamin Y. Kong, Shaun Chou, Deepal Wakade, Matteo S. Carlino, Pablo Fernandez-Penas
Publikováno v:
Case Reports in Medicine, Vol 2017 (2017)
There are reported cases of diphencyprone used in treating cutaneous metastases of melanoma. Here, we report a patient with previous primary melanoma on his left back treated with surgical excision and lymphadenectomy, followed by radiotherapy for th
Externí odkaz:
https://doaj.org/article/f98d184b71c246b39efb74e0ba84bbd8
Autor:
Zarnie Lwin, Eng-Siew Koh, Elizabeth H Barnes, Rosemary Harrup, Hui K Gan, Anna K Nowak, Craig Gedye, Sonia Yip, Benjamin Y Kong, Hao-Wen Sim, Jonathon Parkinson, Rosalind Jeffree, Elizabeth J Hovey, Merryn Hall, Emily Tu, Mark B Pinkham, Candace Carter, Anthony Dowling, John S Simes
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Introduction Glioblastoma (GBM) is the most common malignant primary central nervous system cancer in adults. The objective of the Multi-Arm GlioblastoMa Australasia (MAGMA) trial is to test hypotheses in real world setting to improve survival of peo
Externí odkaz:
https://doaj.org/article/e3e6c47aec9f4f8cacc7e973ad7a136f
Autor:
Clarke, Joe Q. Wei, Alexander Yuile, Malinda Itchins, Benjamin Y. Kong, Bob T. Li, Nick Pavlakis, David L. Chan, Stephen J.
Publikováno v:
Biomedicines; Volume 11; Issue 7; Pages: 1827
Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::8bb63e59180d94837958600c2cf2e637
Autor:
Richard A. Scolyer, Georgina V. Long, Richard F. Kefford, Matteo S. Carlino, John F. Thompson, Serigne Lo, Valerie Jakrot, Robyn P.M. Saw, Julie R. Howle, Adam J. Cooper, Benjamin Y. Kong, Elizabeth Liniker, Alexander Guminski, Jason Madore, Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain
Gain in immune cell counts and Kaplan-Meier progression free survival curves.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bdc91ab7ba907841dd1a031c458b199
https://doi.org/10.1158/1078-0432.22466861.v1
https://doi.org/10.1158/1078-0432.22466861.v1
Autor:
Richard A. Scolyer, Georgina V. Long, Richard F. Kefford, Matteo S. Carlino, John F. Thompson, Serigne Lo, Valerie Jakrot, Robyn P.M. Saw, Julie R. Howle, Adam J. Cooper, Benjamin Y. Kong, Elizabeth Liniker, Alexander Guminski, Jason Madore, Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain
Purpose: Disruption of PD-L1/cytotoxic T-cell PD-1 signaling by immune checkpoint inhibitors improves survival in cancer patients. This study sought to identify changes in tumoral PD-L1 expression and tumor-associated immune cell flux with anti-PD-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::359b1255f0501e503e687e5d46471a7b
https://doi.org/10.1158/1078-0432.c.6526457
https://doi.org/10.1158/1078-0432.c.6526457
Autor:
Benjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, Anna K Nowak, Elizabeth J Hovey, Rosalind Jeffree, Rosemary Harrup, Jonathon Parkinson, Hui K Gan, Mark B Pinkham, Sonia Yip, Merryn Hall, Emily Tu, Candace Carter, Eng-Siew Koh, Zarnie Lwin, Anthony Dowling, John S Simes, Craig Gedye
IntroductionGlioblastoma (GBM) is the most common malignant primary central nervous system cancer in adults. The objective of the Multi-Arm GlioblastoMa Australasia (MAGMA) trial is to test hypotheses in real world setting to improve survival of peop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b97516e26ac47154b148b622c9b9fc25